Navigation Links
Rigel Announces Third Quarter 2011 Financial Results
Date:11/1/2011

o the increase in research and development expenses related to Rigel's R343 program for asthma and its topical JAK3 inhibitor program for discoid lupus, partially offset by the completion of the transfer of the fostamatinib open label extension study to AZ in September 2010, and by a decrease in preclinical expenses for the oral JAK3 inhibitor program for transplant rejection.

For the nine months ended September 30, 2011, Rigel reported a net loss of $60.2 million, or $0.99 per basic and diluted share, compared to a net income of $55.1 million, or $1.06 and $1.05 per basic and diluted share, respectively, for the same period of 2010.

As of September 30, 2011, Rigel had cash, cash equivalents and available-for-sale securities of $265.7 million, compared to $177.3 million as of December 31, 2010. Rigel expects to end 2011 with more than $245.0 million in cash, cash equivalents and available-for-sale securities, which Rigel expects to be sufficient to fund operations into 2014.

"As outlined at our recent investor/analyst day, we expect to initiate two separate Phase 1 clinical trials this year with our oral and topical JAK3 compounds.  We anticipate following those trials in mid-2012 with the launch of a Phase 2 study in asthma with our inhaled syk inhibitor, R343," said James M. Gower, chairman and chief executive officer of Rigel.

(Note: Visit www.rigel.com to replay Rigel's October 13, 2011 investor/analyst day webcast presentation on R343 in asthma and its pipeline programs.)

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related target
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel to Present at Two Upcoming Investor Conferences
2. Rigel to Present at Wells Fargo Securities Healthcare Conference
3. Rigel to Present at Jefferies Global Healthcare Conference
4. Rigel Announces Pricing of Public Offering of Common Stock
5. Rigel Announces Proposed Public Offering of Common Stock
6. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
7. Rigel Announces First Quarter Financial Results
8. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
9. Rigel to Present at Three Upcoming Investor Conferences
10. Rigel Announces Participation at Two Investor Conferences
11. Rigel to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Seeger Weiss LLP is reporting that on July ... letter to C.R. Bard, the manufacturer of Inferior vena ... correct violations the agency found at two of Bard,s facilities. ... FDA cited them during Inspectional Observations that occurred on November ... Tempe, AZ , location and on October 6, 2014, ...
(Date:7/31/2015)... , July 31, 2015 ... Review, 2015 market research report that provides an ... stage using data sourced from in-house databases, secondary ... syringes and needles market products pipeline spread across ... supported with 73 tables and 5 figures is ...
(Date:7/31/2015)... According to a new market research ... Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), ... Global Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment ... 2020, at a CAGR of 7.6%.from 2015 to 2020. ... T ables and 37 F ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4
... Pa., Feb. 16, 2011 AirPal, a medical device ... of allowance from the U.S. Patent Office for its ... for situations such as difficult airway management, laryngoscopies, diagnostic ... founded in 1982, now holds more than a dozen ...
... YORK, Feb. 16, 2011 Get content from ... The European Parliament is expected ... prevent falsified medicines from entering the legal distribution ... packages have reached patients in the last years. ...
Cached Medicine Technology:AirPal Receives Patent for Inflatable Patient Positioning Systems 2
(Date:7/31/2015)... ... , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and ... of Exilis non-surgical fat reduction in New York. Due to its unparalleled level ... clientele. Many patients travel to New York to get their non-surgical skin tightening ...
(Date:7/31/2015)... ... 31, 2015 , ... The 2nd annual Ride to Fight On will start ... 3, 2015. The Ride to Fight On is a cycling fundraiser that benefits the ... West Clinic and The University of Tennessee Health Science Center. A health and wellness ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and ... True North Conference Center. The medical community, social workers, law enforcement, and government ... more aligned in the effort to better understand and combat sex trafficking. Lead ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... SOUTH WINDSOR, Conn., Oct. 1 UTC Power, ... today announced it has,acquired Dome- Tech Group, a ... and New York City. Financial terms were not ... reduce energy costs,and improve overall efficiency. It facilitates ...
... genetics may be to blame, researchers suggest, , , MONDAY, ... is generally considered a good thing, new research suggests ... harm the health of the fetus. , Expectant ... per deciliter (mg/dL) gave birth -- on average -- ...
... Measures to Recognize Value and Enhance Payments, ... private insurers threaten the future of many of ... ability to continue serving all,patients, concludes a new ... New York State (CHCANYS), and funded by CHCANYS ...
... 2007 Two studies in the October issue of ... the use of colonoscopy to screen for colorectal cancer. ... or adenomaspre-cancerous growths that may develop into colorectal cancerson ... with only a few small polyps can be screened ...
... Newer ultrasound and magnetic resonance (MR) imaging tests ... and cirrhosis of the liver, according to three ... Clinical Gastroenterology and Hepatology. , With further research, ... the need for biopsiesprocedures done to obtain a ...
... of the first large-scale studies to examine the association of ... dwelling of older women finds that poorer sleep is associated ... according to a study published in the October 1 issue ... E. Goldman, PhD, of the University of Pittsburgh, was based ...
Cached Medicine News:Health News:UTC Power Acquires Dome-Tech Group 2Health News:Mom's Low Cholesterol Tied to Preemie Births 2Health News:Mom's Low Cholesterol Tied to Preemie Births 3Health News:Commercial Insurers' Reimbursement Rate to New York's Community Health Centers Jeopardizes Care 2Health News:Commercial Insurers' Reimbursement Rate to New York's Community Health Centers Jeopardizes Care 3Health News:Commercial Insurers' Reimbursement Rate to New York's Community Health Centers Jeopardizes Care 4Health News:Studies lend insights into colorectal cancer screening 2Health News:Studies lend insights into colorectal cancer screening 3Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 3Health News:Journal SLEEP: disturbed sleep linked to poorer daytime function in older women 2Health News:Journal SLEEP: disturbed sleep linked to poorer daytime function in older women 3
... Intended for the quantitative determination ... serum or plasma. Liquid buffer ... Phosphate tablets must be purchased ... method. Kinetic reaction. Wavelength: 340 ...
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Intended for the quantitative determination of total protein in serum. Reaction: endpoint. Wavelength: 540 nm. Linearity: 12 g/dL (120 g/L). Ready to use liquid reagent....
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
Medicine Products: